This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cadence Stock Plunges 10% YTD: How Should You Play the Stock?
by Vaishali Doshi
CDNS' robust portfolio amid increasing design activity is promising, but external risks warrant caution. Investors should wait for a better entry point.
Is Most-Watched Stock Synopsys, Inc. (SNPS) Worth Betting on Now?
by Zacks Equity Research
Synopsys (SNPS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Synopsys Dips 22% in a Year: Should You Buy, Sell or Hold the Stock?
by Subham Roy
Despite the near-term challenges, SNPS' strong positioning in AI-driven semiconductor design makes the stock worth holding.
CRDO Plunges 31% YTD: Buy, Sell or Hold the Stock Post Q3 Earnings?
by Nilanshi Mukherjee
Credo Technology suffers from competitive pressures and macroeconomic uncertainties despite growing demand for AI-driven solutions.
Synopsys, Inc. (SNPS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Synopsys (SNPS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Credo Technology Stock Ahead of Q3 Earnings: To Buy or Not to Buy?
by Nilanshi Mukherjee
CRDO's fiscal third-quarter performance is set to gain from AI demand, but valuation and competition risks make it a cautious bet.
SNPS Plunges 21% in a Year: Should You Hold or Fold the Stock?
by Subham Roy
Synopsys suffers from valuation pressures and macroeconomic uncertainties. However, its strong fundamentals make the stock worth retaining.
Synopsys Q1 Earnings Beat: Will Upbeat Outlook Lift SNPS Stock?
by Zacks Equity Research
SNPS' Q1 results reflect strength in EDA and other segments, offset by a decline in the Design IP revenues.
Synopsys (SNPS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Synopsys (SNPS) give insight into how the company performed in the quarter ended January 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Synopsys (SNPS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Synopsys (SNPS) delivered earnings and revenue surprises of 7.83% and 0.16%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?
Synopsys to Report Q1 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
SNPS' first-quarter performance is likely to have benefited from the rising adoption of EDA, IP solutions and Synopsys.ai platform.
Should You Buy, Sell or Hold Cadence Stock Post Q4 Earnings?
by Vaishali Doshi
CDNS' robust portfolio amid increasing design activity is promising, but external risks warrant caution. Investors should wait for a better entry point.
Unlocking Q1 Potential of Synopsys (SNPS): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Synopsys (SNPS) for the quarter ended January 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Synopsys (SNPS) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Synopsys (SNPS) stood at $493.97, denoting a -1.4% change from the preceding trading day.
Ansys (ANSS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ansys (ANSS) delivered earnings and revenue surprises of 11% and 0.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Synopsys (SNPS) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Synopsys (SNPS) closed at $522.53 in the latest trading session, marking a -1.09% move from the prior day.
Synopsys, Inc. (SNPS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Synopsys (SNPS). This makes it worthwhile to examine what the stock has in store.
Is It Worth Investing in Synopsys (SNPS) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Synopsys (SNPS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Synopsys (SNPS) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Synopsys (SNPS) reachead $533.30 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Should You Buy, Sell or Hold Credo Stock at its P/S of 24.76X?
by Nida Ali Saigal
While CRDO is benefiting from its innovative portfolio and growth in AI connectivity, competitive pressures and evolving challenges pose headwinds.
Do Options Traders Know Something About Synopsys (SNPS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Synopsys (SNPS) stock based on the movements in the options market lately.
Synopsys (SNPS) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Synopsys (SNPS) stood at $525.48, denoting a -0.17% change from the preceding trading day.
Investors Heavily Search Synopsys, Inc. (SNPS): Here is What You Need to Know
by Zacks Equity Research
Synopsys (SNPS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Synopsys (SNPS) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Synopsys (SNPS) closed the most recent trading day at $551.54, moving +1.26% from the previous trading session.
Is Synopsys (SNPS) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Synopsys (SNPS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?